Conversely, the high expression of ERCC1 mRNA indicated a detrimental prognosis for patients with Stage IV GC; similar outcomes were also observed between ERCC2 and Stage I/IV, ERCC4 and Stage I/II, and ERCC6 and Stage I/II; however, there was no influence on OS for the expression of ERCC3 by clinical stage. The gene discussed is ERCC2; the disease is gastric cancer.